Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer

Chin-Yau Chen\(^1,2\), Chih-Yung Yang\(^1,3\), Yen-Chung Chen\(^4\), Chia-Wen Shih\(^5\), Su-Shun Lo\(^2\) and Chi-Hung Lin\(^1\)*

### Abstract

**Background:** Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase receptor that is overexpressed in 25 to 30% of human breast cancers and is preferentially localized in lipid rafts. Stomatin is a membrane protein that is absent from the erythrocyte plasma membrane in patients with congenital stomatocytosis and is the major component of the lipid raft.

**Results:** In a total of 68 clinical cases of HER2-positive breast cancer, the absence of stomatin expression was associated with a decreased 5-year survival (65% vs. 93%, \(p=0.005\)) by survival analysis. For stage I-III HER2-positive breast cancer, the absence of stomatin expression was associated with a decreased 5-year disease-free survival (57% vs. 81%, \(p=0.016\)) and was an independent prognostic factor by multivariate analysis. Negative stomatin expression predicts distant metastases in a hazard ratio of 4.0 (95% confidence interval from 1.3 to 12.5).

**Conclusions:** These results may suggest that stomatin is a new prognostic indicator for HER2-positive breast cancer.

**Keywords:** Breast cancer, Stomatin, HER2, Tumor biomarkers

**Abbreviations:** AUC, Area under curve; CI, Confidence interval; CMF, Classical CMF chemotherapy, including cyclophosphamide, methotrexate, and fluorouracil; ER, Estrogen receptor; FISH, Fluorescence in situ hybridization; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; ROC, Receiver operating curve

### Background

Human epidermal growth factor receptor-2 (HER2) is an important transmembrane tyrosine kinase receptor that is overexpressed in 25 to 30% of human breast cancers [1]. The HER2 receptor is able to promote cell proliferation and is preferentially localized in lipid rafts, which are special sphingolipid-rich and cholesterol-rich membrane microdomains; these microdomains control activation HER2 by decreasing HER2 homodimerization and lowering the subsequent spontaneous activation of the receptor [2]. Trastuzumab (Herceptin®) is a humanized monoclonal antibody that binds to HER2 and inhibits the proliferation and survival of HER2-positive breast cancers [3].

Stomatin is a membrane protein that is absent from the erythrocyte plasma membrane in patients with congenital haemolytic anaemia or stomatocytosis [4, 5]. Northern blot analysis has revealed a widespread cellular distribution of stomatin in reticulocytes, bone marrow, kidney, brain, gut and heart as well as various cell lines [6]. Stomatin is the major component of the lipid raft in the plasma membrane of epithelial cell lines, erythrocytes, and platelet alpha granules [7–11]. Two of the few well-known functions of stomatin are, firstly, the direct modulation of the activity of the acid-sensing ion channel and, secondly, the control of glucose transporter type 1 activity [12, 13]. In addition, it has been shown that hypoxia up-regulates stomatin expression in the cerebral cortex of rats and alveolar epithelial cells [14, 15]. However, since the discovery of the stomatin in 1982, the
function of stomatin across a range of different tissues still remains unknown [4, 6, 16].

Stomatin has been shown to have decreased expression in cancer cells [17]. According to the Swedish Human Protein Atlas project, immunohistochemical analysis of stomatin protein expression reveals that more than 75 % of normal breast glandular and myoepithelial cells are strongly positive for this protein [18]. In contrast, in breast cancer, the expression of stomatin in these cells was 31 % (7/23) negative, 39 % weak (9/23), 26 % moderate (6/23), and 4 % (1/23) strong positive when tissue microarrays were analyzed by immunohistochemistry [18].

Although stomatin is expressed in a significant proportion of breast cancers, the relationship between stomatin expression and breast cancer has not been explored in detail. Recently reported by Arkhipova and colleagues in 2014, stomatin is down-regulated in non-small cell lung cancer and is associated with lymph node metastases [19]. This is the first and the only one study to demonstrate that stomatin has a role in carcinogenesis. In comparison, stomatin-like protein 2, which shows a high degree of sequence similarity to stomatin, had been reported to be associated with a decreased overall survival among breast cancer [20], pulmonary squamous carcinoma [21], glioma [22], endometrial adenocarcinoma [23], laryngeal squamous carcinoma [24], esophageal squamous carcinoma [25] and colorectal cancer [26] patients.

Stomatin is the major component of lipid raft where HER2 is known to be clustered and therefore it seems likely that stomatin expression may have an impact on the pathology of HER2-positive breast cancer. In the present study, the relationship of stomatin expression and the clinical survival outcome was explored for patients with HER2-positive breast cancer.

Methods

The archival formalin-fixed paraffin-embedded tissue samples obtained from women diagnosed of infiltrating ductal carcinoma of female breast from 2001 to 2012. The women of histologies other than infiltrating ductal carcinoma were excluded. All HER2-positive cases were either HER2 immunohistochemistry 3+ or 2+ (medium positive) which was further confirmed by fluorescence in situ hybridization (FISH) to identify HER2 gene amplification [27]. There were 5 cases excluded where the HER2 immunohistochemistry results were 2+ but the FISH studies failed. Tumor grade was defined according to the (Scarff) Bloom-Richardson (BR) grading system. The results for ER, PR, and HER2 were obtained from the medical records. Cases where ER and PR were found in more than 5 % of the tumor cells were considered to be positive. Cancer staging was based on the American Joint Committee on Cancer (AJCC seventh Edition). All the patients were operated by either one of the two breast surgeons (C-Y Chen and S-S Lo). Chemotherapy was given according to the institutional guidelines and policy of National Health Insurance Administration in Taiwan. Anthracycline chemotherapy was unrestricted but taxane chemotherapy was insurance-paid only for patients whose cancer was locally advanced or metastatic. For targeted therapy, palliative trastuzumab therapy was insurance-paid when distant metastasis occurred. In patients without a distant event, adjuvant trastuzumab was insurance-paid for patients with positive lymph node status and this policy was only effective after 2010. The duration of trastuzumab therapy was allowed for 1 year at most. In this study, no patient had ever received targeted therapy other than trastuzumab. The study was held in the National Yang-Ming University Hospital, located in the north I-Lan County, Taiwan. The clinical outcomes of the patients were surveyed until December 31, 2014. Institutional review board approval was obtained before acquisition of patient health information.

Tissue sections (4 μm thick) were subjected to heat-induced antigen retrieval in the presence of 0.01 M sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker. Immunohistochemical staining was performed using a polyclonal primary antibody against stomatin (Atlas, HPA011419, Uppsala, Sweden) that was diluted in sodium citrate buffer, pH 6.0 for 30 min using a pressure cooker.

Immunostaining was scored by the researcher (C-Y Chen) and the junior pathologist (Y-C Chen), who were blinded to the patients’ outcome and other clinicopathological parameters. Discordant scores were reevaluated by the senior pathologist (C-W Shih), and a consensus score was used for further analysis. Two features, intensity and extent of immunoreactivity, were assessed as described in a previous report by Chang and colleagues [21]. The intensity of the immunostaining was classified in four categories: 0, no brown particles in the tumor cytoplasm or cell membrane; 1, faint brown staining of cell membrane; 2, weak but definite brown staining of cell membrane; and 3, deep brown staining of cell membrane together with staining of cytoplasm (Fig. 1). The percentage of positive cells was determined and classified into four groups: 1, fewer than 25 % positive tumor cells; 2, 25 to 50 % positive tumor cells; 3, 51 to 75 % positive tumor cells; and 4, more than 75 % positive tumor cells. The immunostaining index was the product of the two scores. We produced time-dependent receiver operating characteristics (ROC) curves [28, 29] for...
evaluation of the immunostaining indices. Area under curve (AUC) at 2- and 5-year survival was 0.765 and 0.543, respectively, suggesting a decrease in the statistical power of stomatin immunoreactivity over time, which may be explained by the early relapse of the HER2-positive breast cancer. The optimal cutoff values were 2 for 5-year-survival ROC and 7 for 2-year-survival ROC. Therefore, we defined positive expression of stomatin protein as a staining index of 4 or more, while a staining index from 0 to 3 was indicative of negative stomatin expression.

Statistical analyses were performed using STATA for Windows 10.0 (StataCorp, College Station, TX). The Student’s t test and Fisher’s exact test were used for statistical analysis as appropriate. We estimated the survival curves using the Kaplan-Meier product limit method [30]. Breast cancer death was defined as death related to distant metastases. Distant disease-free survival was defined as time to distant metastasis, excluding local or regional recurrence. The log-rank test was used to assess the association of survival with stomatin expression. Cox regression analysis was performed to compute hazard ratios and 95 % confidence intervals (CI) and to evaluate the effects of confounding factors during the multivariate analysis. For all statistical tests, \( p < 0.05 \) was considered to be significant. All \( p \) values were two-sided.

**Results**

Using 68 HER2-positive and 58 HER2-negative samples of infiltrating ductal carcinomas of the female breast, stomatin protein expression was found to be localized mainly in the plasma membrane and partially in the cytosol. For HER2-positive patients, the overall immunohistochemistry staining results showed weak or absent staining (staining index <4) in 32 cases (47 %) and positive staining (staining index ≥4) in 36 cases (53 %). There was no statistical difference in patient age, cancer grade, cancer stage, and expression of estrogen receptor/progesterone receptor among women of positive stomatin expression compared with those of negative stomatin expression (Table 1). There was not statistical difference in types of surgery (mastectomy vs. lumpectomy) (Table 1). Most women received an anthracycline-based chemotherapy as first-line adjuvant chemotherapy. For women of HER2-positive cancers, there were 4 received CMF chemotherapy (classical CMF: cyclophosphamide, methotrexate, and fluorouracil) and one woman received taxane only because of heart disease. There were 5 women of HER2-positive cancer did not receive any adjuvant chemotherapy all, including 2 women of early stage and 3 women who refused chemotherapy. There was not statistical difference in types of chemotherapy (Table 1). The proportions of patient who had ever received trastuzumab therapy were 42 % (15/36) in stomatin-positive group and 47 % (15/32) in stomatin-negative group, where there was no statistical difference in the proportions in receiving trastuzumab (Table 1).

In the follow-up of 65 women of stage I-III HER2-positive infiltrating ductal carcinomas, mean follow-up time was 5.0 years. Kaplan-Meier plot (Fig. 2) showed that the 5-year breast cancer-specific survival rates were 93 % (95 % confidence interval = 76 to 98 %) for women of positive stomatin expression and 65 % for women of negative stomatin expression (95 % confidence interval = 38 to 83 %, \( p = 0.005 \)). Namely, negative stomatin expression was significantly associated with a lower 5-year-survival rate. In comparison, there was no survival difference in patients with HER2-negative breast cancers. In women of HER2-negative cancers, the 5-year breast cancer-specific survival rates were 84 % (95 % confidence interval = 67 to 92 %) for women of positive stomatin expression and 94 % for women of negative stomatin expression (95 % confidence interval = 67 to 99 %, \( p = 0.193 \)).

In the follow-up of 65 women of stage I-III HER2-positive cancer, there were lung metastases in 5, bone metastases in 4, liver metastases in 3, lung & bone metastases in 1, lung & liver metastases in 2, distant lymph nodes metastases in 1, and local recurrence without a distant metastasis in two women. When the woman of local recurrence without a distant event was not
regarded as failure of disease-free status, 5-year distant disease-free survival were 81 % (95 % confidence interval = 60 to 92 %) for women of positive stomatin expression and 57 % for women of negative stomatin expression (95 % confidence interval = 33 to 75 %, \( p = 0.016 \), Fig. 3). In comparison, there was no difference in patients with HER2-negative breast cancers. The 5-year distant disease-free survival rates were

| Patient Characteristics | HER2-positive Stomatin (+) (n = 36) | Stomatin (−) (n = 32) | \( p \) values | HER2-negative Stomatin (+) (n = 38) | Stomatin (−) (n = 20) | \( p \) values |
|------------------------|-----------------------------------|--------------------------|--------------|-----------------------------------|--------------------------|--------------|
| Mean age (year)        | 53                                | 58                       | 0.109*       | 54                                | 52                       | 0.659*       |
| Grade                  |                                   |                           |              |                                   |                           |              |
| I                      | 6                                 | 4                        | 0.432†       | 3                                 | 1                        | 0.882†       |
| II                     | 27                                | 22                       |              | 30                                | 15                       |              |
| III                    | 3                                 | 6                        |              | 5                                 | 4                        |              |
| Stage                  |                                   |                           |              |                                   |                           |              |
| I                      | 9                                 | 5                        | 0.420†       | 13                                | 5                        | 0.857†       |
| II                     | 13                                | 17                       |              | 12                                | 8                        |              |
| III                    | 13                                | 8                        |              | 12                                | 7                        |              |
| IV                     | 1                                 | 2                        |              | 1                                 | 0                        |              |
| Estrogen receptor      |                                   |                           |              |                                   |                           |              |
| Positive               | 21                                | 17                       | 0.807†       | 27                                | 16                       | 0.541†       |
| Negative               | 15                                | 15                       |              | 11                                | 4                        |              |
| Progesterone receptor  |                                   |                           |              |                                   |                           |              |
| Positive               | 20                                | 14                       | 0.466†       | 25                                | 16                       | 0.366†       |
| Negative               | 16                                | 18                       |              | 13                                | 4                        |              |
| Hormonal therapy       |                                   |                           |              |                                   |                           |              |
| No                     | 17                                | 13                       | 0.631†       | 10                                | 4                        | 0.751†       |
| Yes                    | 19                                | 19                       |              | 28                                | 16                       |              |
| Surgery                |                                   |                           |              |                                   |                           |              |
| Mastectomy             | 22                                | 18                       | 0.711†       | 32                                | 15                       | 0.540†       |
| Lumpectomy             | 14                                | 13                       |              | 5                                 | 5                        |              |
| No surgery             | 0                                 | 1                        |              | 1                                 | 0                        |              |
| Chemotherapy           |                                   |                           |              |                                   |                           |              |
| None                   | 3                                 | 2                        | 0.702†       | 10                                | 9                        | 0.333†       |
| Adjuvant/Neoadjuvant   |                                   |                           |              |                                   |                           |              |
| Anthracycline          | 20                                | 20                       |              | 23                                | 8                        |              |
| Anthracycline + Taxane | 8                                 | 7                        |              | 4                                 | 3                        |              |
| CMF \( ^5 \)           | 3                                 | 1                        |              | 0                                 | 0                        |              |
| Taxane                 | 1                                 | 0                        |              | 0                                 | 0                        |              |
| Palliative             |                                   |                           |              |                                   |                           |              |
| Anthracycline          | 1                                 | 0                        |              | 1                                 | 0                        |              |
| Anthracycline + Taxane | 0                                 | 2                        |              | 0                                 | 0                        |              |
| Trastuzumab therapy    |                                   |                           |              |                                   |                           |              |
| No                     | 21                                | 17                       | 0.175†       | N/A                               | N/A                       | N/A          |
| Adjuvant               | 12                                | 7                        |              | N/A                               | N/A                       | N/A          |
| Palliative             | 3                                 | 8                        |              | N/A                               | N/A                       | N/A          |

*Student's \( t \) test; †Fisher's exact test; \( ^5 \)CMF: classical CMF, cyclophosphamide, methotrexate, and fluorouracil
64 % (95 % confidence interval = 46 to 77 %) for women of positive stomatin expression and 74 % for women of negative stomatin expression (95 % confidence interval = 46 to 88 %, \( p = 0.479 \)) for HER2-negative patients.

For women of HER2-positive cancers, when either local recurrences or distant metastases were regarded as failure, the 5-year disease-free survival were 79 % (95 % confidence interval = 58 to 90 %) for women of positive stomatin expression and 59 % for women of negative stomatin expression (95 % confidence interval = 36 to 77 %, \( p = 0.037 \)).

Although hormonal receptors expression, cancer stage, and adjuvant trastuzumab therapy were all known prognostic factors for HER2-positive breast cancer, multivariate analyses revealed stomatin was an independent factor for cancer metastases (\( p = 0.017 \), Table 2) for stage I-III HER2-positive breast cancers. Negative stomatin
expression predicts distant metastases in a hazard ratio of 4.0 (95% confidence interval from 1.3 to 12.5, Table 2).

**Discussion**

The present study provides evidence showing a correlation between stomatin protein expression and HER2-positive breast cancer prognosis. Compatible with a previous immunohistochemistry study, which showed that 31% of the breast cancers were negative and 39% weak for stomatin staining, the overall immunohistochemistry staining in our study showed negative staining in 47% (32/68) of samples and positive staining in 53% (36/68) of samples. Because there was no previous study to define the positivity according the expression level of stomatin, we defined the cutoff point of positive expression to be a staining index of 4 or more according to a preliminary time-dependent ROC analysis. It was found that negative stomatin expression was associated with a decreased breast cancer-specific survival and disease-free survival using survival analyses. When distant metastases were defined as cancer recurrence for patients of stage I-III, stomatin was also an independent prognostic factor using multivariate analysis in this study.

Although stomatin-like protein 2, which is a member of the stomatin protein family, has been widely reported to be related to various kinds of cancers, there is only one report up to the present indicating an association between stomatin expression and carcinogenesis [19]. Arkhipova’s and colleagues recently reported that down-regulation of stomatin mRNA was correlated with positive lymph node status in 48 patients [19]. In our study, we initially proposed that lipid-raft localized stomatin might be able to modulate the activity of the HER2-positive breast cancer. The results that absence of stomatin expression might predict distant metastases in HER2-positive breast cancer are comparable to that of Arkhipova’s study for lung cancer [19].

One reason why previous researchers may have overlooked the relationship between stomatin and carcinogenesis may be because only a subgroup of breast cancers, namely the HER2-positive cancers, is affected by stomatin expression. In our study, when the 58 patients with HER2-negative breast cancer were analyzed, there was no survival difference between the stomatin-positive group and the stomatin-negative group. Although why stomatin down-regulation is associated with metastases in HER2-positive cancers remains uncertain, our results may suggest an interaction between HER2 receptor and stomatin in the lipid raft microdomains.

In Taiwan, 90% of the invasive breast cancers are infiltrating ductal carcinoma and less than 4% are infiltrating lobular carcinoma, with smaller percentages in other histology [31]. For reducing bias among different histologies, we chose women of the commonest histological type, infiltrating ductal carcinoma, as our study subjects. In our preliminary study for the histologies other than infiltrating ductal carcinoma, we can not make any conclusion in the influence of stomatin expression to cancer outcomes because the sample size is too small. Further large studies are needed to confirm the relationship between stomatin expression and disease outcomes in other histological types.

Gene expression patterns have distinguished several subtypes of breast carcinomas [32]. In a study reported by Prat et al., all molecular subtypes were identified in the 468 clinical HER2-positive tumors, including HER2-enriched (47%), luminal B (28.2%), basal-like (14.1%), and luminal A (10.7%) [33]. The molecular subtypes significantly affected survival outcomes [33, 34]. In our study, although stomatin was an independent factor in multivariate analysis, the molecular patterns of the tumors were unknown. Future studies exploring gene expression profiles are warranted.

By definition, disease-free survival usually includes local or regional recurrence in addition to distant metastases. However, the impact of local recurrences on survival remains uncertain. Local recurrence itself may be caused by failed local treatment but not by cancer progression. In this study, we defined disease-free survival as time to distant recurrence, excluding local or regional recurrence. Our study provided the valuable results that negative stomatin expression predicts distant metastases in a hazard ratio of 4.0 (95% confidence interval from 1.3 to 12.5) in multivariate analyses.

---

**Table 2** Multivariate Cox model for distant metastases-free survival in women of HER2-positive infiltrating ductal carcinoma, stage I-III (n = 65)

| Parameter            | Risk ratio (95% CI)   | p    |
|----------------------|-----------------------|------|
| Hormonal receptors* |                       | 0.405|
| ER (+) or PR (+)     | 1.0 (referent)        |      |
| ER (−) and PR (−)    | 1.5 (0.6 to 4.3)      |      |
| Stage                |                       | 0.016|
| I–II                 | 1.0 (referent)        |      |
| III                  | 3.5 (1.3 to 9.9)      |      |
| Adjuvant trastuzumab |                       | 0.147|
| Yes                  | 1.0 (referent)        |      |
| No                   | 3.1 (0.7 to 14.8)     |      |
| Stomatin expression  |                       | 0.017|
| Positive             | 1.0 (referent)        |      |
| Negative             | 4.0 (1.3 to 12.5)     |      |

*ER estrogen receptor, PR progesterone receptor

*CI confidence interval
In randomized controlled trials, patients receiving adjuvant trastuzumab showed a significant reduction in mortality and recurrence as compared to those of no adjuvant treatment [35]. The limitation of this study was that the adjuvant trastuzumab was not used for most women because of national insurance policy. Only women had positive lymph nodes were afforded adjuvant trastuzumab and this policy was effective after 2010. Because the patients who had ever received adjuvant trastuzumab were a minor group (28 %, 19 of 68, Table 1) and had a short follow-up time, the influence of trastuzumab treatment on stomatin expression could not be well explored. A clinical trial recruiting more patients is needed in the future. However, in the multivariate analyses, stomatin expression was an independent prognostic indicator from trastuzumab treatment, with a higher hazard ratio than that of adjuvant trastuzumab (hazard ratio 4.0 vs. 3.1). This result may suggest a different pathway of cancer progression in stomatin compared to that of HER2 receptor

Conclusions

Our findings suggest stomatin as one potential prognostic factor that predicts the progression in HER2-positive breast cancer. Further studies investigating the mechanism whereby stomatin affects HER2-positive breast cancer and how stomatin interacts with HER2 are needed.

Acknowledgements

The authors thank Dr. Pei-Shi Hung in her help with bench works.

Funding

The study was supported by National Science Council Project NSC 99-2314-B-010-045, MOST 104-2320-B-010-043-MY3, MOST 105-2319-B-801-001, Taiwan, Republic of China.

Availability of data and materials

The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

C-Y C, C-S L and C-H L analyzed and interpreted the patient data and were major contributors in writing the manuscript. C-Y C, C-S L and C-H L performed the histological examination. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The Institutional Review Board of National Yang-Ming University Hospital approved this study. (IRB No.: 2011A011).

Author details

1Institute of Microbiology and Immunology, National Yang-Ming University, 155, Sec.2, Li-Nong St, Taipei 11221, Taiwan, Republic of China. 2Department of Surgery, National Yang-Ming University Hospital, Yilan County, Taiwan, Republic of China. 3Department of Pathology, National Yang-Ming University Hospital, Yilan County, Taiwan, Republic of China. 4Department of Education and Research, Taipei City Hospital, Taipei, Taiwan, Republic of China. 5Department of Pathology, National Yang-Ming University Hospital, Yilan County, Taiwan, Republic of China. 6Department of Pathology, Lotung Poh-Ai Hospital, Yilan County, Taiwan, Republic of China.

Received: 4 February 2015 Accepted: 3 August 2016

References

1. Salomon DI, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.
2. Nagy P, Vereb G, Sebestyen Z, Horvath G, Lockett SJ, Damjanovich S, et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci. 2002;115(Pt 22):4251–62.
3. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(13):39–51.
4. Lapatinis L, Brand J, Poole K, Daumke O, Lewin GR. Stomatin-domain proteins. Eur J Cell Biol. 2012;91(14):240–5.
5. Stewart GW, Argent BC, Dash BC. Stomatin: a putative cation transport regulator in the red cell membrane. Biochim Biophys Acta. 1993;1225(1):15–25.
6. Stewart GW, Hepworth-Jones BE, Keen JN, Dash BC, Argent AC, Casimir CM. Isolation of cDNA coding for an ubiquitous membrane protein deficient in high Na+, low K+ stomatocytic erythrocytes. Blood. 1992;79(6):1593–601.
7. Snyers L, Umlauf E, Prohaska R. Association of stomatin with lipid-protein complexes in the plasma membrane and the endocytic compartment. Eur J Cell Biol. 1999;78(11):802–12.
8. Salzer U, Prohaska R, Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts. Blood. 2001;97(4):1141–3.
9. Maihofer M, Steiner M, Mosgoeller W, Prohaska R, Salzer U. Stomatin is a major lipid-raft component of platelet alpha granules. Blood. 2002;100(3):897–904.
10. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387(6633):569–72.
11. Mrowczynska L, Salzer U, Perkovska S, Iglis A, Hagerstrand H. Echinophilic proteins of erythrocyte lipid rafts. Blood. 2001;97(4):1141–9.
12. Price MP, Thomson RJ, Eshcol JO, Wemmie JA, Benson CJ. Stomatin modulates gating of acid-sensing ion channels. J Biol Chem. 2004;279(51):53886–91.
13. Montel-Hagen A, Kinet S, Manel N, Mongellaz C, Prohaska R, Battini JL, et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell. 2008;132(6):1039–48.
14. Wang Y, Cao D, Chen J, Liu A, Yu Q, Song X, et al. Distribution of stomatin expressing in the central nervous system and its up-regulation in cerebral cortex of rat by hypoxia. J Neurochem. 2011;116(3):374–84.
15. Chen X, Cai HY, Wang Y, Ma YY, Song LN, Yin LJ, et al. Up-regulation of stomatin expression by hypoxia and glucocorticoid stabilizes membrane-associated actin in alveolar epithelial cells. J Cell Mol Med. 2013;17(7):863–72.
16. Lande WM, Thiemann PV, Mentzer Jr WC. Missing band 7 membrane protein in two patients with high Na, low K erythrocytes. J Clin Invest. 1982;70(6):1273–80.
17. Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Armhey JW, et al. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J Proteome Res. 2006;5(10):2632–41.
18. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248–50.
19. Arkhipova KA, Sheyderman AN, Laktionov KK, Mochalnikova WV, Zborovskaya IB. Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer. 2014;14:100.
22. Song L, Liu L, Wu Z, Lin C, Dai T, Yu C, et al. Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-kappaB/MMP-9 pathway. J Pathol. 2012;226(3):534–43.

23. Cui Z, Zhang L, Hua Z, Cao W, Feng W, Liu Z. Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep. 2007;17(4):829–33.

24. Cao WF, Zhang LY, Liu MR, Tang PZ, Liu ZH, Sun BC. Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol. 2007;38(5):747–52.

25. Zhang L, Ding F, Cao W, Liu Z, Liu W, Yu Z, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12(5):1639–46.

26. Yeeh LC, Loh OK, Gooi BH, Singh M, Gam LH. Hydrophobic protein in colorectal cancer in relation to tumor stages and grades. World J Gastroenterol. 2010;16(22):2754–63.

27. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53(5):374–81.

28. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biom J. 2000;42(3):337–44.

29. R Core Team R: A Language and Environment for Statistical Computing [https://www.R-project.org]. Accessed 24 Aug 2016.

30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

31. Taiwan Cancer Registry [http://tccr.cph.ntu.edu.tw/main.php?Page=N1]. Accessed 24 Aug 2016.

32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.

33. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106(8):1–8.

34. Fälck AK, Ferno M, Bendahl PO, Ryden L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases-aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer. 2013;13:558.

35. Viani GA, Alfonso SL, Stefano EJ, De Fendi LL, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.